188 related articles for article (PubMed ID: 37072346)
1. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
Sharma S; Woods M; Mehta NU; Sauer T; Parikh KS; Schmuck-Henneresse M; Zhang H; Mehta B; Brenner MK; Heslop HE; Rooney CM
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072346
[TBL] [Abstract][Full Text] [Related]
2. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells.
Sharma S; Sauer T; Omer BA; Shum T; Rollins LA; Rooney CM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958791
[TBL] [Abstract][Full Text] [Related]
3.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
4. Robust Identification of Suitable T-Cell Subsets for Personalized CMV-Specific T-Cell Immunotherapy Using CD45RA and CD62L Microbeads.
Mangare C; Tischer-Zimmermann S; Riese SB; Dragon AC; Prinz I; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30897843
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma.
Sharma S; Mehta NU; Sauer T; Dittmer DP; Rollins LA; Rooney CM
Blood Adv; 2024 Apr; ():. PubMed ID: 38640255
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
7. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
8. Adoptive T-Cell Immunotherapy.
Gottschalk S; Rooney CM
Curr Top Microbiol Immunol; 2015; 391():427-54. PubMed ID: 26428384
[TBL] [Abstract][Full Text] [Related]
9. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
10. Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy.
Bachar-Lustig E; Lask A; Eidelstein Y; Or-Geva N; Gidron-Budovsky R; Nathansohn-Levy B; Eyrich M; Liu WH; Dang G; Miranda KC; Ramirez A; Kaur I; Rezvani K; Shpall E; Champlin RE; Nagler A; Shimoni A; Barnees-Kagan S; Reisner Y
Transplant Cell Ther; 2024 Jan; 30(1):71.e1-71.e13. PubMed ID: 37890590
[TBL] [Abstract][Full Text] [Related]
11. Variances in Antiviral Memory T-Cell Repertoire of CD45RA- and CD62L-Depleted Lymphocyte Products Reflect the Need of Individual T-Cell Selection Strategies to Reduce the Risk of GvHD while Preserving Antiviral Immunity in Adoptive T-Cell Therapy.
Mangare C; Tischer-Zimmermann S; Bonifacius A; Riese SB; Dragon AC; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Transfus Med Hemother; 2022 Feb; 49(1):30-43. PubMed ID: 35221866
[TBL] [Abstract][Full Text] [Related]
12. Defective T-helper cell function after T-cell-depleting therapy affecting naive and memory populations.
Heitger A; Winklehner P; Obexer P; Eder J; Zelle-Rieser C; Kropshofer G; Thurnher M; Holter W
Blood; 2002 Jun; 99(11):4053-62. PubMed ID: 12010807
[TBL] [Abstract][Full Text] [Related]
13. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential.
Dunne PJ; Faint JM; Gudgeon NH; Fletcher JM; Plunkett FJ; Soares MV; Hislop AD; Annels NE; Rickinson AB; Salmon M; Akbar AN
Blood; 2002 Aug; 100(3):933-40. PubMed ID: 12130505
[TBL] [Abstract][Full Text] [Related]
15. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.
Omer B; Cardenas MG; Pfeiffer T; Daum R; Huynh M; Sharma S; Nouraee N; Xie C; Tat C; Perconti S; Van Pelt S; Scherer L; DeRenzo C; Shum T; Gottschalk S; Arber C; Rooney CM
Cancer Immunol Res; 2022 Apr; 10(4):512-524. PubMed ID: 35176142
[TBL] [Abstract][Full Text] [Related]
16. Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV
Hernández DM; Valderrama S; Gualtero S; Hernández C; López M; Herrera MV; Solano J; Fiorentino S; Quijano S
Front Immunol; 2018; 9():2291. PubMed ID: 30337929
[TBL] [Abstract][Full Text] [Related]
17. Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells.
Müller N; Landwehr K; Langeveld K; Stenzel J; Pouwels W; van der Hoorn MAWG; Seifried E; Bonig H
Cytotherapy; 2018 Apr; 20(4):532-542. PubMed ID: 29500069
[TBL] [Abstract][Full Text] [Related]
18. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
19. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
20. Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells.
Distler E; Bloetz A; Albrecht J; Asdufan S; Hohberger A; Frey M; Schnürer E; Thomas S; Theobald M; Hartwig UF; Herr W
Haematologica; 2011 Jul; 96(7):1024-32. PubMed ID: 21486863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
